DCs matured in the presence of IL-15 are being investigated as promising components of next-generation DC-based immunotherapies; however, these approaches may require combinatorial strategies to achieve clinically relevant immunity, given the complexity of tumor immune evasion [10]. The gene discussed is IL15; the disease is neoplasm.